Table 3:
Multivariate analysis of factors predicting outcomes after auto-HCT
| Characteristic | Progression free survival | Relapse/Progression | Overall survival | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Disease status at transplant | <0.001 | <0.001 | <0.001 | |||
| ≥ VGPR | Reference | Reference | Reference | |||
| PR | 1.53(1.11-2.11) | 0.008 | 1.4 (1.01-1.96) | 0.04 | 1.55 (1.09-2.2) | 0.01 |
| SD/PD/relapse | 3.6 (2.3-5.8) | <0.001 | 3.3 (2.04-5.45) | <0.001 | 4.3 (2.6-7.2) | <0.001 |
| Missing | 1.8 (0.63- 5.22) | 0.26 | 1.4 (0.44-5.8) | 0.53 | 2.7 (0.99-7.8) | 0.05 |
| Melphalan dose | 0.04 | 0.08 | - | - | ||
| 140 mg/m2 | Reference | Reference | ||||
| 200 mg/m2 | 0.65 (0.44-0.98) | 0.68 (0.45-1.04) | ||||
| Karnofksy performance status | - | - | 0.0018 | |||
| ≥ 90 | Reference | |||||
| < 90 | 1.80 (1.3- 2.49) | 0.004 | ||||
| Missing | 1.79 (0.43- 7.3) | 0.41 | ||||